Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion

Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion

Abstract Background Renal ischemia–reperfusion injury (IRI) is one reason for renal transplantation failure. Recent studies have shown that mitochondrial dynamics is closely related to IRI, and that inhibition or reversal of mitochondrial division protects organs against IRI. Optic atrophy protein 1...

Full description

Bibliographic Details
Main Authors: Wenbo Yang, Xiaoli Li, Liujie He, Shuyang Zhu, Shicong Lai, Xiaopeng Zhang, Zixiong Huang, Biyue Yu, Chunping Cui, Qiang Wang
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cellular & Molecular Biology Letters
Subjects:
Renal ischemia–reperfusion injury
Empagliflozin
SGLT2i
Inflammation
Mitochondrial dynamics
OPA1
Online Access:https://doi.org/10.1186/s11658-023-00457-6

Internet

https://doi.org/10.1186/s11658-023-00457-6

Similar Items